{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:29:51Z","timestamp":1785518991510,"version":"3.56.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009340","name":"Children's Discovery Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.tips.2019.07.012","type":"journal-article","created":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T08:21:15Z","timestamp":1566634875000},"page":"803-806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Alport Syndrome Therapeutics: Ready for Prime-Time Players"],"prefix":"10.1016","volume":"40","author":[{"given":"Kohei","family":"Omachi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1510-8714","authenticated-orcid":false,"given":"Jeffrey H.","family":"Miner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2019.07.012_bb0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161802","article-title":"X-linked and autosomal recessive Alport syndrome: pathogenic variant features and further genotype\u2013phenotype correlations","volume":"11","author":"Savige","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.tips.2019.07.012_bb0010","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.kint.2017.12.018","article-title":"Alport syndrome: a unified classification of genetic disorders of collagen IV \u03b1345: a position paper of the Alport Syndrome Classification Working Group","volume":"93","author":"Kashtan","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.tips.2019.07.012_bb0015","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00467-018-3985-4","article-title":"Expert consensus guidelines for the genetic diagnosis of Alport syndrome","volume":"34","author":"Savige","year":"2019","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.tips.2019.07.012_bb0020","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2215\/CJN.00580116","article-title":"Alport syndrome in women and girls","volume":"11","author":"Savige","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.tips.2019.07.012_bb0025","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3390\/ijms20030519","article-title":"Kidney injury by variants in the COL4A5 gene aggravated by polymorphisms in slit diaphragm genes causes focal segmental glomerulosclerosis","volume":"20","author":"Frese","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2019.07.012_bb0030","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12882-018-0906-5","article-title":"COL4A5 and LAMA5 variants co-inherited in familial hematuria: digenic inheritance or genetic modifier effect?","volume":"19","author":"Voskarides","year":"2018","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.tips.2019.07.012_bb0035","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/ki.2014.326","article-title":"Pathology vs. molecular genetics: (re)defining the spectrum of Alport syndrome","volume":"86","author":"Miner","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.tips.2019.07.012_bb0040","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.matbio.2018.04.008","article-title":"Alport syndrome and Pierson syndrome: diseases of the glomerular basement membrane","volume":"71\u201372","author":"Funk","year":"2018","journal-title":"Matrix Biol."},{"key":"10.1016\/j.tips.2019.07.012_bb0045","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1523-1755.2003.00779.x","article-title":"Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome","volume":"63","author":"Gross","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.tips.2019.07.012_bb0050","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/ki.2011.407","article-title":"Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy","volume":"81","author":"Gross","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.tips.2019.07.012_bb0055","doi-asserted-by":"crossref","DOI":"10.5402\/2012\/436046","article-title":"Safety and efficacy of the ACE-inhibitor ramipril in Alport syndrome: the double-blind, randomized, placebo-controlled, multicenter phase III EARLY PRO-TECT Alport trial in pediatric patients","volume":"2012","author":"Gross","year":"2012","journal-title":"ISRN Pediatr."},{"key":"10.1016\/j.tips.2019.07.012_bb0060","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1681\/ASN.2012020148","article-title":"Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy","volume":"24","author":"Savige","year":"2013","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.tips.2019.07.012_bb0065","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1172\/JCI75852","article-title":"Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways","volume":"125","author":"Gomez","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.tips.2019.07.012_bb0070","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.tips.2019.07.012_bb0075","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1681\/ASN.2017101062","article-title":"Should we increase GFR with bardoxolone in Alport syndrome?","volume":"29","author":"Baigent","year":"2018","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.tips.2019.07.012_bb0080","doi-asserted-by":"crossref","first-page":"F120","DOI":"10.1152\/ajprenal.00456.2015","article-title":"Albumin contributes to kidney disease progression in Alport syndrome","volume":"311","author":"Jarad","year":"2016","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.tips.2019.07.012_bb0085","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.tips.2019.07.012_bb0090","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.kint.2016.02.018","article-title":"Endothelin A receptor activation on mesangial cells initiates Alport glomerular disease","volume":"90","author":"Dufek","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.tips.2019.07.012_bb0095","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1681\/ASN.2018010091","article-title":"DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS","volume":"29","author":"Trachtman","year":"2018","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.tips.2019.07.012_bb0100","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/00325481.2019.1601404","article-title":"SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence","volume":"131","author":"Davidson","year":"2019","journal-title":"Postgrad. Med."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614719301658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614719301658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T09:08:44Z","timestamp":1759050524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614719301658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0165614719301658"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2019.07.012","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alport Syndrome Therapeutics: Ready for Prime-Time Players","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2019.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}